289
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Etoposide and Cisplatin in Advanced Esophageal Cancer: A preliminary report

, &
Pages 807-809 | Published online: 07 Aug 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jan Fagerberg, Dag Stockeld & Rolf Lewensohn. (1994) Combined Treatment Modalities in Esophageal Cancer: Should chemotherapy be included?. Acta Oncologica 33:4, pages 439-450.
Read now

Articles from other publishers (3)

Dongfeng Sun, Qingfa Chen, Zhibo Gai, Fengxia Zhang, Xiaoqing Yang, Wensi Hu, Chengyu Chen, Guangjie Yang, Severin Hörmann, Gerd. A. Kullak-Ublick & Michele Visentin. (2021) The Role of the Carnitine/Organic Cation Transporter Novel 2 in the Clinical Outcome of Patients With Locally Advanced Esophageal Carcinoma Treated With Oxaliplatin. Frontiers in Pharmacology 12.
Crossref
Simon M. Allen, John P. Duffy, S. Jane Darnton, Michael H. Cullen & Hugoe R. Matthews. (1996) Phase II study of mitomycin, ifosfamide and cisplatin in adenocarcinoma of the oesophagus. Cancer Chemotherapy and Pharmacology 37:5, pages 496-498.
Crossref
S.M. Allen, J.P. Duffy, S.J. Walker, S.J. Darnton, M.H. Cullen & H.R. Matthews. (1994) A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus. Clinical Oncology 6:2, pages 91-95.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.